Skip to main content

Recombinant Human PRL-3/PTP4A3 Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 8455-PT

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
8455-PT-050

Key Product Details

Source

E. coli

Accession #

Conjugate

Unconjugated

Applications

Enzyme Activity

Product Specifications

Source

E. coli-derived human PRL-3/PTP4A3 protein
Ala2-Met173, with N-terminal Met and 7-His tag

Purity

>85%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain at 5 μg per lane.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met

Predicted Molecular Mass

20 kDa

SDS-PAGE

23 kDa, reducing conditions

Activity

Measured by its ability to cleave a substrate, p-Nitrophenyl phosphate (pNPP).
The specific activity is >0.4 pmol/min/μg, as measured under the described conditions.

Formulation, Preparation and Storage

8455-PT
Formulation Supplied as a 0.2 μm filtered solution in HEPES, NaCl, DTT and Glycerol.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: PRL-3/PTP4A3

Phosphatase of regenerating liver 3 (PRL-3), also known as protein-tyrosine phosphatase 4A3 (PTP4A3), is a member of the PRL subgroup of PTPases (1). It is preferentially expressed in skeletal muscle and the heart (2). Human PRL-3 shares 97% amino acid sequence identity with mouse and rat PRL-3. Structurally, PRL-3 consists of a five-stranded beta-sheet and six alpha-helices (3, 4). It has been shown to associate with membranes in a farnesylation-dependent manner (5). Both PRL-3 over-expression and attenuation of PRL-3 expression results in cell cycle arrest, suggesting that basal expression levels of this enzyme are important for normal cell cycle progression (6). PRL-3 has been shown to activate NF-kappa B signaling and may itself be regulated by FKBP38 (7, 8). PRL-3 also promotes epithelial to mesenchymal transition, tumor angiogenesis, cell migration, invasion, and metastasis, and it is over-expressed in multiple human cancers (9-18). Src-mediated phosphorylation of PRL-3 may be required for PRL-3-dependent cell migration and invasion (19).

References

  1. Bessette, D.C. et al. (2008) Cancer Metastasis Rev. 27:231.
  2. Zeng, Q. et al. (1998) Biochem. Biophys. Res. Commun. 244:421.
  3. Kozlov, G. et al. (2004) J. Biol. Chem. 279:11882.
  4. Kim, K.A. et al. (2004) FEBS Lett. 565:181.
  5. Zeng, Q. et al. (2000) J. Biol. Chem. 275:21444.
  6. Basak, S. et al. (2008) Mol. Cell 30:303.
  7. Lian, S. et al. (2013) Biochem. Biophys. Res. Commun. 430:196.
  8. Choi, M.S. et al. (2011) Biochem. Biophys. Res. Commun. 406:305.
  9. Wang, H. et al. (2007) Cancer Res. 67:2922.
  10. Liu, Y. et al. (2009) Cancer Biol. Ther. 8:1352.
  11. Pryczynicz, A. et al. (2014) Tumour Biol. 35:6587.
  12. Guo, K. et al. (2006) Cancer Res. 66:9625.
  13. Ming, J. et al. (2014) Pathobiology 81:1.
  14. Zeng, Q. et al. (2003) Cancer Res. 63:2716.
  15. Kato, H. et al. (2004) Clin. Cancer Res. 10:7318.
  16. Al-Aidaroos, A.Q. and Q. Zeng (2010) J. Cell. Biochem. 111:1087.
  17. Jiang, Y. et al. (2011) Cancer Res. 71:234.
  18. Krndija, D. et al. (2012) J. Cell Sci. 125:3883.
  19. Fiordalisi, J.J. et al. (2013) PLoS One 8:e64309.

Long Name

Phosphatase of Regenerating Liver 3

Alternate Names

PRL3, PTP4A3

Entrez Gene IDs

11156 (Human); 19245 (Mouse)

Gene Symbol

PTP4A3

UniProt

Additional PRL-3/PTP4A3 Products

Product Documents for Recombinant Human PRL-3/PTP4A3 Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human PRL-3/PTP4A3 Protein, CF

For research use only

Loading...
Loading...
Loading...